China Universal Asset Management Company’s Relay Therapeutics RLAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$639K Buy
34,138
+2,422
+8% +$35.2K 0.04% 243
2026
Q1
$316K Buy
31,716
+3,473
+12% +$31.1K 0.02% 308
2025
Q4
$239K Sell
28,243
-1,978
-7% -$14.1K 0.02% 332
2025
Q3
$158K Sell
30,221
-4,213
-12% -$16.1K 0.01% 348
2025
Q2
$119K Buy
34,434
+431
+1% +$1.28K 0.01% 349
2025
Q1
$89.1K Sell
34,003
-1,488
-4% -$5.83K 0.01% 364
2024
Q4
$146K Buy
35,491
+9,740
+38% +$53K 0.01% 355
2024
Q3
$182K Buy
25,751
+10,157
+65% +$75.9K 0.02% 310
2024
Q2
$102K Sell
15,594
-9,616
-38% -$65.7K 0.01% 301
2024
Q1
$209K Buy
25,210
+10,953
+77% +$107K 0.03% 283
2023
Q4
$157K Buy
14,257
+11,122
+355% +$93.9K 0.03% 229
2023
Q3
$26.4K Buy
3,135
+1,541
+97% +$16.6K 0.01% 281
2023
Q2
$20K Sell
1,594
-50
-3% -$622 0.01% 268
2023
Q1
$27.1K Buy
1,644
+416
+34% +$7.46K 0.01% 192
2022
Q4
$18.3K Buy
1,228
+208
+20% +$3.98K 0.01% 181
2022
Q3
$23K Buy
+1,020
New +$22.4K 0.01% 148

Other funds holding RLAY

China Universal Asset Management Company's RLAY Position: Q2 2026 in Review

China Universal Asset Management Company increased its Relay Therapeutics (RLAY) stake by 7.6% in Q2 2026, buying an estimated $35.2K and bringing the position to 34,138 shares worth $639K. The position accounts for 0.04% of the portfolio, ranked #243.

China Universal Asset Management Company first reported a position in RLAY in Q3 2022 and has held it in 16 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • China Universal Asset Management Company held 34,138 shares of Relay Therapeutics worth $639K as of Q2 2026.
  • China Universal Asset Management Company bought 2,422 Relay Therapeutics shares in Q2 2026, an estimated $35.2K.
  • Relay Therapeutics made up 0.04% of China Universal Asset Management Company's portfolio in Q2 2026, its #243 holding.
  • China Universal Asset Management Company first reported a position in Relay Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.